Company news
TG Therapeutics, Inc. news in 2024
TG Therapeutics, Inc.'s news releases, calls and decks from 2024, newest first.
TG Therapeutics to Participate in the Evercore HealthCONx Conference
November 28, 2024
TG Therapeutics Ranked Number One Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500™
November 20, 2024
TG Therapeutics Reports Third Quarter 2024 Financial Results and Raises BRIUMVI® (ublituximab-xiiy) Full Year Revenue Guidance
November 3, 2024
TG Therapeutics to Host Conference Call on Third Quarter 2024 Financial Results and Business Update
October 31, 2024
New Data for BRIUMVI® (ublituximab-xiiy) Demonstrate that 92% of Patients with Relapsing Multiple Sclerosis Were Free from Disability Progression After 5 Years of Treatment
September 17, 2024
New BRIUMVI® (ublituximab-xiiy) Data from the ENHANCE Phase 3b Study Show Rapid 30-Minute Infusions are Well Tolerated in Patients with Relapsing Forms of Multiple Sclerosis
September 17, 2024
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI at the 2024 European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting
September 4, 2024
TG Therapeutics Reports Second Quarter 2024 Financial Results and Raises BRIUMVI® (ublituximab-xiiy) Full Year Revenue Guidance
August 5, 2024
TG Therapeutics to Host Conference Call on Second Quarter 2024 Financial Results and Business Update
August 4, 2024
TG Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
June 6, 2024
TG Therapeutics Announces Schedule of Upcoming Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the 2024 Consortium of Multiple Sclerosis Centers Annual Meeting
May 27, 2024
TG Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results
April 30, 2024
TG Therapeutics to Host Conference Call on First Quarter 2024 Financial Results and Business Update
April 29, 2024
TG Therapeutics Awarded National Contract by the Department of Veterans Affairs for BRIUMVI as the Preferred Anti-CD20 for Relapsing Forms of Multiple Sclerosis
April 17, 2024
TG Therapeutics Announces Additional Data Presentations for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting
April 17, 2024
TG Therapeutics Announces Presentation of Data for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting
April 14, 2024
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting
March 7, 2024
TG Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2023 Financial Results
February 27, 2024
TG Therapeutics Announces Issuance of Additional Patents for BRIUMVI® (ublituximab-xiiy)
February 26, 2024
TG Therapeutics Announces European Launch of BRIUMVI® (ublituximab-xiiy)
February 25, 2024
TG Therapeutics to Host Conference Call on Fourth Quarter and Year-End 2023 Financial Results and Business Update
February 22, 2024
TG Therapeutics Provides Preliminary Fourth Quarter and Full Year 2023 Net Revenue and 2024 Anticipated Milestones
January 9, 2024
TG Therapeutics Announces Global License Agreement with Precision BioSciences for the Development and Commercialization of Precision’s Allogeneic CD19 CAR T Cell Therapy Program for the Treatment of Autoimmune Diseases
January 8, 2024
TG Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
January 4, 2024